moderna merck - Search News

Moderna, Merck and melanoma vaccine

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.

· 2d

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

· 2d

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

· 1d

Moderna chairman discusses cancer vaccine breakthrough

Moderna Chairman Noubar Afeyan says the trial results remind him of when his company developed its Covid-19 vaccine.

India Today · 1d

Moderna & Merck Cancer Vaccine Clears Phase 3 Trial | How Personalised mRNA Tech Fights Melanoma

· 10h

Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer

· 1d

From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day

Moderna and the big drugmaker Merck reported that their experimental cancer vaccine extended the time before melanoma recurred in a clinical trial — the first late-stage study of its kind to succeed.

· 1d

Moderna, Merck cancer vaccine scores big win in late-stage melanoma trial

· 1d

Moderna shares get a shot in the arm after cancer vaccine results

2don MSN

Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

21h

Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.

BioSpace

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed the line from promising to proven.

Medical Marketing & Media

Rx Rundown: Moderna, Merck, LEO Pharma and more

The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for certain adults with previously treated multiple myeloma. The drug is made by Bristol Myers Squibb.